Philip J. Gold

基本信息

Career Trajectory

Bio

Presently, he is board certified in medical oncology. Dr. Gold’s clinical investigations on GI tumors, and particularly colorectal cancer treatment, can be found in peer-reviewed publications like the Journal of Clinical Oncology, Seminars in Oncology, and Cancer Investigation. Furthermore, he currently serves as a member of the NCI Colon Task Force, and the Southwest Oncology Group, where he serves as the subcommittee co-chair for colon cancer.

Research Interests

Papers共 61 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients with RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

Kanwal Pratap Singh Raghav,Katherine A Guthrie,Benjamin Tan,Crystal S Denlinger,Marwan Fakih,Michael J Overman,N Arvind Dasari, Larry R Corum, Lee G Hicks, Mital S Patel,Benjamin T Esparaz,Syed M Kazmi, Nitya Alluri,Sarah Colby,Sepideh Gholami,Philip J Gold,E Gabriela Chiorean,Scott Kopetz,Howard S Hochster,Philip A Philip

Journal of clinical oncology official journal of the American Society of Clinical Oncologyno. 11 (2025): 1348-1357

Cited0Views0WOSBibtex

Nivolumab Plus Ipilimumab (N+I) in Patients (pts) with Pancreatic Cancer (PC) with BRCA1/2 Mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Peter Joel Hosein,Michael Rothe,Elizabeth Garrett-Mayer,Ari David Baron,Timothy Lewis Cannon,Evan P. Pisick,Evthokia Hobbs,Kathryn Finch Mileham, Matthew Joseph Tinguely,Marina Frimer,Philip Jordan Gold,Kelsey Klute,Sherise C. Rogers,Vaibhav Sahai,Davendra Sohal,Sachdev P. Thomas, Jerome Dallas Winegarden,Abby Gregory,Susan Halabi,Richard L. Schilsky

Journal of Clinical Oncologyno. 4_suppl (2025): 715-715

Cited0Views0Bibtex

Abstract CT267: Temsirolimus (T) in Patients (pts) with Solid Tumors with AKT1/3 Amplification (amp) or Mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Deepti Behl,Michael Rothe,Pam K. Mangat,Elizabeth Garrett-Mayer, Niklas Mackler,Herbert L. Duvivier,Philip J. Gold,Sapna R. Patel, Regan M. Duffy, Lauren A. Mauro,Eugene R. Ahn,Maria Bell,Carmen J. Calfa,Jean L. Grem,Jens Rueter,Margaret von Mehren,Gina N. Grantham,Abigail Gregory,Dominique C. Hinshaw,Susan Halabi,Richard L. Schilsky

Cancer Researchno. 7_Supplement (2024)

Cited0Views0Bibtex

Temsirolimus (T) in Patients (pts) with Solid Tumors with AKT1/3 Amplification (amp) or Mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

CANCER RESEARCHno. 7 (2024)

Cited0Views0Bibtex

SWOG S2107: Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic And/or Unresectable Colorectal Cancer

Van K. Morris,Katherine A. Guthrie,Scott Kopetz,Rimini Breakstone,Thomas Benjamin Karasic,Zishuo Ian Hu,Sarah Colby,Marwan Fakih,Sepideh Gholami,Philip Jordan Gold,Philip A. Philip

Journal of Clinical Oncology（2024）

Cited2Views0Bibtex

Supplementary Figure 2 from A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)

Aaron J. Scott,Atrayee Basu Mallick, Efrat Dotan,Steven J. Cohen,Philip J. Gold,Howard S. Hochster,Somasundaram Subramaniam, Afsaneh Barzi,George S. Watts,Patrick J. Blatchford,Wells A. Messersmith

openalex（2023）

Cited0Views0Bibtex

116Tip Randomized, Open-Label, Phase II Study of Botensilimab (BOT) Alone and in Combination with Balstilimab (BAL) Versus Standard-of-care in Patients with Refractory Metastatic Colorectal Cancer

E. Van Cutsem,M. Fakih,N.H. Segal,B. Johnson,A. Kardosh, A. Philipovskiy, S. Krishnamurthi,P.J. Gold,J. Dekervel,B.L. Schlechter, J. Grossman,M.E. Elez Fernandez, N. Vardiashvili, A.A. Azambuja,C. Eng,M.P. Ducreux,T. André,J. Tabernero,H.J. Lenz, M. Hidalgo

Immuno-Oncology and Technology (2023): 100588

Cited0Views0Bibtex

Palbociclib (P) in Patients (pts) with Solid Tumors with CDK4 or CDK6 Amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

M. F. Khalil,M. Rothe,P. K. Mangat,E. Garrett-Mayer,K. F. Mileham,E. R. Ahn, H. L. Duvivier, L. C. Farrington,M. Akce, D. Behl,P. J. Gold,V. K. Chiu,N. Vijayvergia,C. Calfa, A. Gaba,F. Meric-Bernstam,S. M. Schuetze, A. Gregory,S. Halabi,R. L. Schilsky

ANNALS OF ONCOLOGY (2023): S265-S266

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Director of Clinical Research

Papers共 61 篇Author StatisticsCo-AuthorSimilar Experts